STOCK TITAN

Cingulate - CINGW STOCK NEWS

Welcome to our dedicated page for Cingulate news (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company pioneering precision drug delivery through its Precision Timed Release™ (PTR™) platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.

Access real-time information about Cingulate's ADHD treatment candidates like CTx-1301, anxiety disorder therapies including CTx-2103, and global patent expansions. Our curated news collection covers FDA submissions, clinical trial results, technology licensing agreements, and financial disclosures - all critical for evaluating the company's market position.

Key updates include progress toward the mid-2025 NDA submission for CTx-1301, international patent grants, and developments in the PTR™ platform's application across therapeutic areas. Bookmark this page to stay informed about Cingulate's innovations in precision medication delivery and its impact on treatment adherence challenges.

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has secured a $3 million grant from a private foundation to accelerate the development of CTx-2103 (buspirone) for anxiety treatment. The grant will be distributed in three $1 million tranches, with the first payment scheduled for May 1st and subsequent tranches tied to development milestones.

CTx-2103 aims to be the first once-daily formulation of buspirone in the $5.5 billion U.S. anxiety market ($11.6 billion globally). The foundation will receive quarterly royalties of $500,000 after commercialization, capped at $3.5 million total. The development leverages Cingulate's proprietary Precision Timed Release™ (PTR™) drug delivery platform technology.

This initiative addresses a significant medical need, as anxiety disorders affect approximately 31% of U.S. adults and represent the most common mental health concern in America, according to the National Institutes of Mental Health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
none
-
Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has completed a Pre-NDA meeting with the FDA regarding its lead ADHD treatment asset CTx-1301 (dexmethylphenidate HCl). The company remains on schedule for a New Drug Application submission in mid-2025.

The company recently released Phase 3 safety data for CTx-1301 and results from a food effect study using a single 50-mg dose in healthy adults. The safety profile has remained consistent across nine clinical trials. CTx-1301 is positioned to be the first true once-daily stimulant medication for ADHD treatment throughout the active day, utilizing Cingulate's proprietary Precision Timed Release™ (PTR™) drug delivery platform.

A final analysis combining both adult and pediatric safety and efficacy data will be included in the upcoming NDA submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.75%
Tags
-
Rhea-AI Summary

Cingulate reported its full year 2024 and Q4 results, highlighting significant progress towards NDA submission for its ADHD treatment CTx-1301. The company secured a $17.5 million increase in working capital, extending cash runway into Q4 2025. Key developments include:

- Scheduled FDA Pre-NDA meeting for April 2, 2025
- Completed safety data from Phase 3 pediatric and adolescent studies with no serious adverse events
- Finished final FDA-required food effect study
- Secured European patent for CTx-1301

Financial highlights:
- Cash position: $12.2 million as of December 31, 2024
- Working capital: $7.5 million
- R&D expenses decreased to $9.4 million from $15.5 million in 2023
- Net loss reduced to $15.5 million from $23.5 million in 2023

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68.57%
Tags
Rhea-AI Summary

Cingulate (NASDAQ: CING) has announced positive safety results from its final Phase 3 trials for CTx-1301, their lead ADHD treatment asset. The data encompasses two Phase 3 pediatric and adolescent studies (fixed dose and dose optimization) and a food effect study with healthy adults using a 50mg dose.

Key safety findings show no serious treatment emergent adverse events (TEAEs) or deaths, with no clinically relevant trends in TEAEs overall. The food effect study's medical findings align with previous 25mg dose results, indicating CTx-1301 can be taken with or without food.

The company has submitted these results to the FDA ahead of an in-person Pre-NDA meeting scheduled for April 2, 2025. Cingulate plans to file for FDA approval in mid-2025, positioning CTx-1301 as the first true once-daily stimulant medication for treating ADHD throughout the entire active day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has completed its final FDA-required food effect study for CTx-1301, its lead ADHD treatment drug. The study evaluated a single 50mg dose of CTx-1301 (dexmethylphenidate) to determine if the medication can be taken with or without food, with no serious adverse events reported.

Data readout regarding bioavailability is expected in Q2 2025. A previous study in 2022 with a 25mg dose demonstrated that CTx-1301 could be taken regardless of food intake. The company is developing CTx-1301 to be the first true once-daily stimulant medication for ADHD treatment over an entire active day. Cingulate targets submission of the New Drug Application (NDA) to the FDA by mid 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.04%
Tags
none
-
Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has secured a financing transaction worth $5 million in net proceeds through a non-convertible, unsecured promissory note of $5.48 million with an accredited investor. The note carries a 9% annual interest rate and matures in 18 months. The funds will extend the company's cash runway into Q4 2025, supporting clinical, manufacturing, and regulatory activities, including the planned NDA submission for CTx-1301 targeted for mid-2025. The private placement was made under Section 4(a)(2) of the Securities Act and/or Regulation D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
67.13%
Tags
none
Rhea-AI Summary

Cingulate Inc. reported Q3 2024 financial results, highlighting a $19.5M increase in working capital. The company raised $12.5M in capital during Q3, extending cash runway into Q3 2025. Net loss decreased to $3.2M from $6.0M year-over-year, with R&D expenses dropping to $1.4M from $3.9M. The company secured European patents for its lead ADHD asset CTx-1301 in up to 30 territories and regained Nasdaq compliance. Cingulate remains on track for mid-2025 New Drug Application submission of CTx-1301.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.79%
Tags
-
Rhea-AI Summary

Shane J. Schaffer, Chairman and CEO of Cingulate (NASDAQ: CING), appeared on the nationally syndicated Big Biz Show to discuss Cingulate's lead Phase 3 asset, CTx-1301, for the treatment of ADHD. Schaffer highlighted the company's Precision Timed Release™ (PTR™) drug delivery platform, which aims to advance next-generation pharmaceutical products. The discussion included plans for the commercialization of CTx-1301 and potential applications of PTR™ technology in other therapeutic areas. The Big Biz Show, hosted by Bob “Sully” Sullivan, is broadcast globally through partners like iHeart Radio and the American Forces Network.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
none
-
Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has initiated its final FDA-required study for CTx-1301, a dexmethylphenidate-based treatment for ADHD. The food effect study is expected to yield results by the end of 2024. The company has also raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility. This capital infusion strengthens Cingulate's balance sheet and supports the advancement of CTx-1301 towards NDA submission, targeted for mid-2025. Additionally, Cingulate has received notification from Nasdaq confirming its compliance with listing requirements, addressing previous concerns about potential delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
Rhea-AI Summary

Cingulate (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Schaffer will discuss the company's recent European patent, the ADHD market, and potential expansion of Cingulate’s Precision Timed Release™ (PTR™) drug delivery platform into other therapeutic areas. The event can be viewed live on Benzinga's YouTube channel and later on Cingulate's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Cingulate

Nasdaq:CINGW

CINGW Rankings

CINGW Stock Data

3.40M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY